Aflibercept
- Generic Name
- Aflibercept
- Brand Names
- Eylea, Zaltrap, Yesafili
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 862111-32-8
- Unique Ingredient Identifier
- 15C2VL427D
- Background
Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It contains approximately 15%...
- Indication
The opthalmic agent is used for the treatment of neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and retinopathy of prematurity (ROP).
...
- Associated Conditions
- Branch Retinal Vein Occlusion With Macular Edema, Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Macular Edema With Central Retinal Vein Occlusions, Metastatic Colorectal Cancer (CRC), Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD), Retinopathy of Prematurity (ROP)
- Associated Therapies
- -
Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-06-28
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- NSABP Foundation Inc
- Registration Number
- NCT01889680
A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan
- Conditions
- Interventions
- First Posted Date
- 2013-06-20
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 62
- Registration Number
- NCT01882868
- Locations
- 🇯🇵
Investigational Site Number 392002, Sunto-Gun, Japan
🇯🇵Investigational Site Number 392005, Suita-Shi, Japan
🇯🇵Investigational Site Number 392017, Fukuoka-Shi, Japan
Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy
- First Posted Date
- 2013-05-20
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- Tennessee Retina
- Target Recruit Count
- 10
- Registration Number
- NCT01857544
- Locations
- 🇺🇸
Tennessee Retina, PC, Nashville, Tennessee, United States
Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2018-01-31
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 37
- Registration Number
- NCT01843725
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
Study of PRN and Every 2months Intravitreal Aflibercept for Age Related Macular Degeneration
- First Posted Date
- 2013-04-04
- Last Posted Date
- 2015-10-07
- Lead Sponsor
- Nihon University
- Target Recruit Count
- 100
- Registration Number
- NCT01824225
- Locations
- 🇯🇵
Surugadai Nihon university hospital, Chiyoda-ku, Tokyo, Japan
Efficacy and Safety Study of ESBA1008 Versus EYLEA®
- Conditions
- Interventions
- First Posted Date
- 2013-02-22
- Last Posted Date
- 2016-02-09
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 173
- Registration Number
- NCT01796964
Treatment for Presumed Ocular Histoplasmosis
- First Posted Date
- 2013-02-13
- Last Posted Date
- 2014-06-16
- Lead Sponsor
- John Kitchens, MD
- Target Recruit Count
- 40
- Registration Number
- NCT01790893
- Locations
- 🇺🇸
Southeast Retina, Augusta, Georgia, United States
🇺🇸Cincinnati Eye Institute, Cincinnati, Ohio, United States
🇺🇸Retina Associates of Kentucky, Lexington, Kentucky, United States
Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
- First Posted Date
- 2013-02-01
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 19
- Registration Number
- NCT01782443
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 39
- Registration Number
- NCT01749956
- Locations
- 🇺🇸
Virginia Cancer Institute, Richmond, Virginia, United States
🇺🇸Baptist Hospital East, Louisville, Kentucky, United States
🇺🇸Space Coast Cancer Center, Titusville, Florida, United States
FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-12-11
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 64
- Registration Number
- NCT01747551
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.